MiR-126 Regulates Proliferation and Invasion in the Bladder Cancer BLS Cell Line by Targeting the PIK3R2-Mediated PI3K/Akt Signaling Pathway [Retraction]
Authors Xiao J, Lin H, Zhu Y, Zhu Y, Chen L
Received 5 March 2021
Accepted for publication 5 March 2021
Published 10 March 2021 Volume 2021:14 Pages 1859—1860
Xiao J, Lin H, Zhu Y, Zhu Y, Chen L. Onco Targets Ther. 2016;9:5181–5193.
The Editor and Publisher of OncoTargets and Therapy wish to retract the published article. It came to our attention that several figures within the paper appeared to be duplicated, specifically:
● Figure 4A panels Noninfected and BLS-Lv-vector appear to be duplicated with images from Figure 3B panels Control and NC from Wang et al: MicroRNA-200b inhibits pituitary tumor cell proliferation and invasion by targeting PKCα (https://doi. org/10.3892/etm.2017.4681).
● Figure 4A panel BLS-Lv-miR126 appears to be duplicated with an image from Figure 3B panel Mimics from Wang et al: MicroRNA-200b inhibits pituitary tumor cell proliferation and invasion by targeting PKCα
● Figure 8A, the two right panels appear to be duplicated.
● Figure 8B, the two left panels and the far right panel appear to be duplicated.
We attempted to contact the authors of this article but despite multiple attempts received no response. The Editor has determined the findings of the study are no longer valid and requested for the article to be retracted.
Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
This retraction relates to this paper
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]